This review discusses the current state of multicancer early detection tests, the role of machine learning in their ...

ARC101, a potential best-in-class T-cell engager that targets solid tumors expressing CLDN6, is being assessed in a ...

Ken Kato, MD, discussed the FDA approval of tislelizumab for the first-line treatment of esophageal squamous cell carcinoma.

During a Case-Based Roundtable® event, Ryan W. Jacobs, MD, discussed a patient who received 2 prior lines of therapy for ...

Saeed Sadeghi, MD, discusses the findings on transfusion independence achieved with treatment for patients with low-risk myelodysplastic syndrome.

Jacob E. Berchuck, MD, highlights challenges in adopting liquid biopsy for PSMA expression and its potential to revolutionize precision medicine in prostate cancer.